標題：OBI-992，以TROP2為標靶的抗體藥物複合體（ADC），在動物癌症模式中展現優異的抗腫瘤藥效
摘要編號：1893 / 海報編號：23/4
<a href="https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/2024-AACR-OBI-992-Animal-Study-Poster-Final.pdf">PDF LINK</a> 
<img loading="lazy" decoding="async" class="alignnone size-full wp-image-38548" src="https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/OBI_AACR-Animal-Study-Poster_FINAL-to-Printer-04-02-2024-scaled.jpg" alt="" width="2560" height="1670" srcset="https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/OBI_AACR-Animal-Study-Poster_FINAL-to-Printer-04-02-2024-scaled.jpg 2560w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/OBI_AACR-Animal-Study-Poster_FINAL-to-Printer-04-02-2024-1536x1002.jpg 1536w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/OBI_AACR-Animal-Study-Poster_FINAL-to-Printer-04-02-2024-2048x1336.jpg 2048w" sizes="(max-width: 2560px) 100vw, 2560px" />
標題：新穎TROP2抗體藥物複合體OBI-992特性分析研究
摘要編號：3130 / 海報編號：21/11
<a href="https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/05/2024-AACR-OBI-992-In-vitro-Study-Poster-Final_compressed-1.pdf">PDF LINK</a> 
<img loading="lazy" decoding="async" class="alignnone wp-image-40777 size-full" src="https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-In-Vitro-Poster-Layout_final_1April2024-scaled.webp" alt="" width="2560" height="1670" srcset="https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-In-Vitro-Poster-Layout_final_1April2024-scaled.webp 2560w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-In-Vitro-Poster-Layout_final_1April2024-300x196.webp 300w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-In-Vitro-Poster-Layout_final_1April2024-1200x783.webp 1200w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-In-Vitro-Poster-Layout_final_1April2024-150x98.webp 150w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-In-Vitro-Poster-Layout_final_1April2024-1536x1002.webp 1536w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-In-Vitro-Poster-Layout_final_1April2024-2048x1336.webp 2048w" sizes="(max-width: 2560px) 100vw, 2560px" />
標題：全新的專一性醣鍵結ADC平台可增進ADC穩定性，並提升動物實驗中的抗腫瘤藥效
摘要編號：3149 / 海報編號：21/30
<a href="https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/2024-AACR-GlycOBI-with-OBI-902-Poster-Final.pdf">PDF LINK</a>
<img loading="lazy" decoding="async" class="alignnone size-full wp-image-38546" src="https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/2024-AACR-GlycOBI-with-OBI-902-Poster-Final-scaled.jpg" alt="" width="2560" height="1609" srcset="https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/2024-AACR-GlycOBI-with-OBI-902-Poster-Final-scaled.jpg 2560w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/2024-AACR-GlycOBI-with-OBI-902-Poster-Final-1536x965.jpg 1536w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/2024-AACR-GlycOBI-with-OBI-902-Poster-Final-2048x1287.jpg 2048w" sizes="(max-width: 2560px) 100vw, 2560px" />
標題：新穎TROP2抗體藥物複合體OBI-992，展現優越的藥物動力學/藥效特性和良好的安全性
摘要編號：7179 / 海報編號：24/20
<a href="https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/2024-AACR-GlycOBI-with-OBI-902-Poster-Final.pdf">PDF LINK</a>
<img loading="lazy" decoding="async" class="alignnone wp-image-40778 size-full" src="https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-PK-PD-Layout_final_1April2024-scaled.webp" alt="" width="2560" height="1670" srcset="https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-PK-PD-Layout_final_1April2024-scaled.webp 2560w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-PK-PD-Layout_final_1April2024-300x196.webp 300w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-PK-PD-Layout_final_1April2024-1200x783.webp 1200w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-PK-PD-Layout_final_1April2024-150x98.webp 150w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-PK-PD-Layout_final_1April2024-1536x1002.webp 1536w, https://s3.ap-northeast-1.amazonaws.com/obipharma.com/live/wp-content/uploads/2024/04/AACR-2024-OBI-992-PK-PD-Layout_final_1April2024-2048x1336.webp 2048w" sizes="(max-width: 2560px) 100vw, 2560px" />

經營團隊

董事會

關於我們

研發產品線

技術平台

學術發表

研究與發展

新聞發佈

重大公告

活動訊息

基本資料

公司治理

利害關係人

每月營收

年度報告

財務報告

股價資訊

公司簡報

投資總覽

永續發展

人才招募

企業文化

聯絡我們

新聞與活動

台灣浩鼎 前進北美生技展

浩鼎將在 AACR 2024年會  發表四篇論文

AACR 2024年會 - 論文展示 OBI-992及 GlycOBI™ ADC平台的最新研究

標題：OBI-992，以TROP2為標靶的抗體藥物複合體（ADC），在動物癌症模式中展現優異的抗腫瘤藥效 摘要 [&hellip;]

AACR 2024年會 - 論文展示 OBI-992及 GlycOBI™ ADC平台的最新研究 - OBI Pharma 台灣浩鼎

Default Confirmation

If you need to contact us, please fill out the following form.

By submitting this form, you agree to our <a href="/privacy-policy" target="_blank">Privacy Policy</a>.

Enter consent agreement text here.  The Consent Field will store this agreement text with the form entry in order to track what the user has consented to.

Admin Notification

New submission from {form_title}

Contact Us - EN

投資